Sage Therapeutics (NASDAQ: SAGE) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.
This table compares Sage Therapeutics and Brainstorm Cell Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Brainstorm Cell Therapeutics||N/A||-56.24%||-51.18%|
Risk and Volatility
Sage Therapeutics has a beta of 2.94, suggesting that its share price is 194% more volatile than the S&P 500. Comparatively, Brainstorm Cell Therapeutics has a beta of 2.31, suggesting that its share price is 131% more volatile than the S&P 500.
Insider and Institutional Ownership
12.7% of Brainstorm Cell Therapeutics shares are held by institutional investors. 6.1% of Sage Therapeutics shares are held by company insiders. Comparatively, 23.7% of Brainstorm Cell Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
This is a summary of recent ratings and recommmendations for Sage Therapeutics and Brainstorm Cell Therapeutics, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Brainstorm Cell Therapeutics||0||0||1||0||3.00|
Sage Therapeutics currently has a consensus target price of $78.14, suggesting a potential upside of 2.28%. Brainstorm Cell Therapeutics has a consensus target price of $9.00, suggesting a potential upside of 116.35%. Given Brainstorm Cell Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Brainstorm Cell Therapeutics is more favorable than Sage Therapeutics.
Earnings and Valuation
This table compares Sage Therapeutics and Brainstorm Cell Therapeutics’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Sage Therapeutics||N/A||N/A||-$222.35 million||($6.05)||-12.63|
|Brainstorm Cell Therapeutics||N/A||N/A||-$5.06 million||($0.28)||-14.86|
Brainstorm Cell Therapeutics is trading at a lower price-to-earnings ratio than Sage Therapeutics, indicating that it is currently the more affordable of the two stocks.
Brainstorm Cell Therapeutics beats Sage Therapeutics on 8 of the 11 factors compared between the two stocks.
About Sage Therapeutics
SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor. The Company’s next-generation product candidates, SAGE-217 and SAGE-689, also target the GABAA receptor system. The Company is focused on developing drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The Company’s chemistry platform is focused on the chemical scaffolds of endogenous or chemically modified synthetic neuroactive steroid compounds that are allosteric modulators of GABAA or N-Methyl-D-aspartic acid or N-Methyl-D-aspartate (NMDA) receptors.
About Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others. Its subsidiary, Brainstorm Cell Therapeutics Ltd. (the Israeli Subsidiary), holds rights to commercialize the technology, NurOwn. NurOwn is in clinical development for the treatment of ALS. The Company has completed over two clinical trials of NurOwn in patients with ALS at Hadassah Medical Center (Hadassah). The first study, a Phase I/II safety and efficacy study of NurOwn in ALS patients administered either intramuscularly or intrathecally. The Company conducted Phase IIa combined (intramuscular and intrathecal) treatment, dose-escalating trial. It had completed treatment of over 10 patients in its ALS Phase IIa NurOwn dose-escalating clinical trial.
Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.